US20070053895A1 - Method of treating and diagnosing parkinsons disease and related dysautonomic disorders - Google Patents
Method of treating and diagnosing parkinsons disease and related dysautonomic disorders Download PDFInfo
- Publication number
- US20070053895A1 US20070053895A1 US11/555,697 US55569706A US2007053895A1 US 20070053895 A1 US20070053895 A1 US 20070053895A1 US 55569706 A US55569706 A US 55569706A US 2007053895 A1 US2007053895 A1 US 2007053895A1
- Authority
- US
- United States
- Prior art keywords
- pharmaceutical preparation
- mg
- individual
- enzymes
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/94—Pancreatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21001—Chymotrypsin (3.4.21.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22002—Papain (3.4.22.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
Abstract
A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.
Description
- This application is a continuation-in-part of U.S. application Ser. No. 10/730,567, filed Dec. 8, 2003, which is a continuation of U.S. application Ser. No. 09/929,592 filed Aug. 14, 2001, which claims the benefit of U.S. Provisional Application No. 60/224,991, filed Aug. 14, 2000. Each of these applications is herein incorporated in its entirety by reference.
- The present invention generally relates to a method for treating Parkinson's disease and related dysautonomic disorders and a method for diagnosing individuals with Parkinson's disease or related dysautonomic disorders. More particularly, the invention relates to a diagnosis method of analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) that provides an indication of whether the individual has, or can develop, Parkinson's disease or a related dysautonomic disorder, as well as a therapeutic method for treating Parkinson's disease or a related dysautonomic disorder by the administration of pancreatic/digestive enzymes.
- The nervous system of the body is comprised of two separate systems, the central nervous system and the peripheral nervous system. The peripheral nervous system is comprised of the somatic or “voluntary” nervous system and the autonomic or “automatic” nervous system.
- The autonomic nervous system is further broken down into the parasympathetic, sympathetic, and enteric nervous systems. Additionally, it is known that the adrenal glands help to support the sympathetic responses of the autonomic nervous system and the enteric nervous system deals exclusively with the gastrointestinal system. With some overlap they each control various autonomic functions of the body through regulation so neurotransmitter releases which affect nervous control
- Acetylcholine is a neurotransmitter used by the parasympathetic nervous system, while nor epinephrine is utilized by the sympathetic nervous system. The adrenal glands secrete epinephrine which help to support the sympathetic nervous system. Norepinephrine and epinephrine together with a substance most affected in Parkinson's disease; dopamine, make up a category of hormones known as the catecholamines.
- The enteric nervous system exerts tremendous control over the digestive processes of the body, including gastrointestinal blood flow, secretion absorption, and overall breakdown of food. The enteric nervous system contains a significant number of neurons, thought to be as numerous as those found in the central nervous system. The enteric nervous system is comprised of three types of neurons: sensory, motor, and interneurons. While the sensory neurons are able to determine the environment of the lumen including chemical, ph, thermal and mechanical changes within the lumen, the motor neurons, including those to the pancreatic exocrine cells, control digestion and play a major role in the breakdown of food and the ultimate absorption of nutrients.
- There are two network of nerve plexuses which constitute the enteric nervous system: the myenteric plexus and the submucous plexus. The two plexuses extend from the esophagus to the anus and thus run almost the entire route of the gastrointestinal system.
- The submucous plexus, which is not continuous throughout the gastrointestinal tract, is located in the submucosal layer of the gastrointestinal tract. Its primary function is to assess the luminal activity of the GI system, and therefore exert tremendous control over GI blood flow, secretions into the lumen and absorption rates of such things as nutrients, water, and hormones such as secretin which is secreted into the blood stream as a result of the enteric nervous systems determination of low Ph of the bolus of food entering the small intestine. This further ultimately determines the role of the pancreatic/digestive enzymes.
- The myenteric plexus controls digestive motility and is located in between the longitudinal and circular layers of muscle in the tunica muscularis. It is this segment of the enteric nervous system which may be initially affected in Parkinson's disease.
- The overall digestive process includes the communication between the autonomic (enteric) nervous system and the central nervous system as digestion does not happen solely as a function of the autonomic nervous system. Additionally, there are significant enteric hormones that affect digestion, including secretin, which are under the control of the autonomic nervous system. From the autonomic nervous system, there is an overall increase in the stimulation of digestion from the parasympathetic branch of the autonomic nervous system which occurs mainly through the secretion of the neurotransmitter acetylcholine, while norepinephrine, secreted by the sympathetic nervous system decreases digestion in the gastrointestinal tract.
- Dysautonomias are diseases and syndromes that relate to the autonomic nervous system of the individual. Hence in individuals afflicted with dysautonomias, many normal and automatic functions of the body are left with poor function or little to no function at all.
- There are a plethora of dysautonomic disorders in which the symptoms of autonomic dysfunction are manifest. For instance, Parkinson's disease is marked by mild to severe autonomic dysfunction including changes in gait, tremor, discoordination, increased salivary flow, and overall loss of autonomic function. Additionally, changes in executive function are typically noted in a Parkinson's patient, often allowing the patient to appear as having Alzheimer's disease and resulting in misdiagnosis. Executive function disorders are also found in autistic children.
- It has been noted that a lack of secretin response, which is directly under the control of the enteric nervous system, may underlie may other conditions. Further, the use of secretin directly as a therapeutic agent may be efficacious as in the case of those with familial dysautonomia.
- Parkinson's disease is widespread throughout the Western hemisphere and was first reported by physician James Parkinson in 1817. Parkinson's disease is first detected as a tremor in a limb, and ultimately progresses to include 3 manifestations: (i) rigidity, which is characterized by “cog-wheel” like movement and “lead-pipe” rigidity; (ii) bradykinesia or slowness in movement, and (iii) postural instability associated with a stooped stance and an impaired gait. These altered movements are features of the motor dysfunction, but in addition there can also be a mental impairment in as many as 40% of all Parkinson's patients.
- It is known that Parkinson's disease is caused by a deficient state of levo-dopamine in the brain. More specifically, levo-dopa induced dyskinesis in Parkinson's patients is thought to be a result of denervation of the substantia nigra. To date, medical science has not found a substrate that would allow an injectable form of levo-dopa to reach the brain and successfully cross the blood brain barrier. The current dopamine replacement therapy is aimed at either direct replacement or mimicking the action at the dopamine receptor sites in the brain. Sinemet™ and Sinemet CR™ are the two major drugs suited to that end. While the levo-dopa therapy can create some beneficial changes initially, those changes generally wane over time, and produce other problems such as severe sleep disturbance, dyskinesias, and constant nausea. Medical approaches to Parkinson's disease include surgical destruction of the tissue of the brain and the insertion of microelectrodes (deep brain electrical stimulation) to effected portions of the brain. The insertion of electrodes has the advantage of being reversible. These interventions, however, are generally transient and neither produces a permanent change in the Parkinsonian state nor reverses the effects of the disease.
- Some authors suggest that Parkinson's disease is a multifactor, neurodegenerative disorder, which evolves due to excessive oxidation. The substantia nigra is susceptible to oxidative damage which supports this theory of the formation of Parkinson's disease. Abnormalities of the oxidative phosphorylation impair the mitochondria of the substantia nigra, and intensify free radical generation.
- While the dyskinesias and loss of executive functioning of the brain receive the most significant mention with respect to Parkinson's disease, other physical manifestations exist that are associated with autonomic dysfunction which are often poorly understood. Some of these manifestations include, e.g.: esophageal reflux, diarrhea, and other gastrointestinal dysfunction. In addition, excessive sweating, sleep disturbances and other symptoms of Parkinson's disease are very similar to those found in familial dysautonomia.
- It has long been held that protein restricted diets, timed protein intake diets, or low protein diets were essential for the absorption of certain medications, especially levo-dopa, in the patient afflicted with Parkinson's disease. Many studies have demonstrated the possibility that the large neutral amino acids (tryptophan, valine, isoleucine, leucine, tyrosine, phenylalanine) may interfere with the absorption of the 1-dopamine. Numerous studies have been performed and much postulation has been made about various diets. It has long been held by the inventor that there was a decrease in protein digestion in the dysautonomic patient, including those with Parkinson's disease. This lack of protein digestion would therefore necessitate an alteration in the protein intake in individuals with this type of dysfunction, including a decrease in the ingestion of certain proteins which may be difficult to digest without the presence of the necessary digestive enzyme and/or proper functioning of the secretin mechanism, and the over-ingestion of protein to make up for that which is not digested when there in an apparent impairment in protein digestive function. For example, if an individual needed 40 grams of protein a day to sustain function, but had only a mechanism which was 10% effective then the individual would gravitate toward a diet which was higher in protein and protein which would be easier to digest.
- This fact has recently been demonstrated in a paper found in Movement Disorders: Protein Intake in Parkinsonian patients using the EPIC food frequency questionnaire by Marczewska on Apr. 18, 2006. In this paper, 45 Parkinson's patients were evaluated using the EPIC food questionnaire. While average caloric intake was normal in the Parkinson's patients, they consumed significantly higher amounts of protein (mainly in the form of vegetable proteins). The overall protein intake was 50% higher than the recommended daily allowance (1.2 g/kg vs. 0.8 g/kg). More importantly, it showed that the more severe the symptoms of the patient, the greater the protein intake by the patient.
- Further, chymotrypsin appears to continue to be a biomarker for those with Parkinson's disease as the chymotrypsin cleaves only essential amino acids. If there is a dearth of chymotrypsin, then the essential amino acids needed by the body will not be available, and a greater ingestion of protein may be needed in order to attain sufficient essential amino acids.
- Accordingly, in view of such findings, a method for determining whether an individual suffering from a dysautonomic disorder and/or any disorder comprising dysautonomic components will benefit from the administration of secretin, or pancreatic/digestive enzymes, would be highly advantageous. In addition, a method for aiding in the diagnosis of individuals who may develop Parkinson's disease and related conditions or symptoms is highly desirable.
- The present invention is directed to methods for aiding in the diagnosis of Parkinson's disease and related disorders, and for treating individuals diagnosed as having Parkinson's disease or related disorders.
- In one embodiment, a method is provided for treating Parkinson's disease patients, including those who are likely to develop the disorder or those who presently have the disorder, through the administration of digestive/pancreatic enzymes.
- In another embodiment, a diagnostic method is provided for determining whether an individual has, or may develop, Parkinson's disease or related disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder. In one embodiment, the diagnostic method analyzes a compound in a stool sample of an individual and correlates the analysis of the compound with a dysautonomic disorder or condition or the lack thereof. In one embodiment, the compound to be analyzed is a pancreatic enzyme, such as chymotrypsin, or any compound that provides an indication of either protein digestion or metabolism, pancreatic function, or an inflammatory process, or a combination thereof. In one embodiment, the analysis determines a quantitative level of the compound in the stool.
- In a further embodiment, a method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder.
- In yet another embodiment, a method for treating a Parkinson's patient with digestive enzymes/pancreatic enzymes involves analyzing a compound in a stool sample of the individual in which the administration of the digestive enzymes/pancreatic enzymes is based on the analysis of the stool sample. In one embodiment, the compound to be analyzed comprises a pancreatic enzyme, such as chymotrypsin, or any compound that provides an indication of either protein digestion or metabolism, pancreatic function, or an inflammatory process, or a combination thereof.
- In yet a further embodiment, a process for analyzing the stool sample involves measuring a quantitative level of a pancreatic enzyme, such as chymotrypsin, present in the stool sample and comparing the measured quantitative level with at least one threshold level to determine the efficacy of the digestive enzyme/pancreatic enzyme administration to the individual. In one embodiment, the threshold level is based on a level of the pancreatic enzyme associated with at least one other individual of the same approximate age that does not have Parkinson's disease.
- In an additional embodiment, a formulation of digestive enzymes/pancreatic enzymes is provided which is efficacious for the treatment of Parkinson's disease and related disorders.
- The features and advantages described herein are not all-inclusive and, in particular, many additional features and advantages will be apparent to one of ordinary skill in the art in view of the drawings, specification, and claims. Moreover, it should be noted that the language used in the specification has been principally selected for readability and instructional purposes, and not to limit the scope of the inventive subject matter.
-
FIG. 1 is a graph demonstrating the decrease in occurrences of constipation in Parkinson's patients after administration of digestive enzymes over a period of 180 days. -
FIG. 2 is a graph demonstrating the increase in the number of bowel movements in Parkinson's patients after administration of digestive enzymes over a period of 180 days. -
FIG. 3 is a graph demonstrating the decrease in occurrences of tremors in Parkinson's patients after administration of digestive enzymes over a period of 180 days. -
FIG. 4 is a graph demonstrating the decrease in occurrences of falls in Parkinson's patients after administration of digestive enzymes over a period of 180 days. -
FIG. 5 is a graph demonstrating the changes in ambulation in Parkinson's patients after administration of digestive enzymes over a period of 180 days. -
FIG. 6 is a graph demonstrating the difference in the fecal chymotrypsin levels of Parkinson's and non-Parkinson's subjects. - The present invention is directed to methods for aiding in the diagnosis of dysautonomic disorders and dysautonomic conditions, and for treating individuals diagnosed as having a dysautonomic disorder and other disorders having dysautonomic components. In one embodiment, a method is provided for determining the presence of abnormal protein digestion and/or pancreatic dysfunction of an individual, especially a child, by analyzing a stool sample of the individual for the quantitative levels of one or more pancreatic enzymes including, but not limited to, chymotrypsin, so as to determine if the individual has, or may develop, a dysautonomic disorder or condition. In another embodiment, a method is provided for determining whether the individual is likely to benefit from the administration of secretin, CCK, VIP, digestive enzymes, other peptides, and/or neuropeptides. Until now, there has been no clear biological marker for dysautonomic disorders or conditions to allow early diagnosis or screening of such disorders or conditions.
- It has been discovered by the inventor herein that a population of individuals suffering from dysautonomic disorders such as Parkinson's disease have abnormal or pathologic levels of pancreatic enzymes such as chymotrypsin in their stools. It is postulated that in dysautonomic syndromes, the partial paresis of the gastrointestinal tract, and therefore the lack of functioning of the secretory cells of the proximal small intestine, preclude the proper formation and/or release of secretin. It is further postulated that this abnormal protein digestion, as reflected by the low levels of pancreatic enzymes such as chymotrypsin, can be improved by the administration of secretin, CCK, VIP, other neuropeptides, peptides, and/or digestive enzymes to thereby ameliorate the symptoms of dysautonomic conditions. Indeed, as a low measure of fecal chymotrypsin, for example, expresses an abnormality of protein digestion and/or pancreatic dysfunction, it is postulated that an improvement of protein digestion to promote normal growth and development of an individual suffering from a dysautonomic disorder or dysautonomic condition by the administration of secretin, CCK, VIP, other neuropeptides and/or peptides and/or digestive enzymes, can ameliorate the dysautonomic symptoms.
- In one embodiment, a stable preparation of digestive/pancreatic enzymes is formed into a dosage formulation containing a therapeutically effective amount of a protease, an amylase, and/or a lipase. The formulation may include additional enzymes, such as pancreatin, chymotrypsin, trypsin, papain and/or papaya. The dosage formulation may be administered by an oral preparation including, but not limited to, an encapsulated tablet, mini-tabs, microcapsule, mini-capsule, time released capsule, sprinkle or other methodology. In one embodiment, the oral preparation is encapsulated using Prosolv technology. Alternatively, the oral preparation may be encapsulated using enteric coating, lipid encapsulation, direct compression, dry granulation, wet granulation, and/or a combination of these methods.
- The dosage formulations may be as follows (USP=U.S. Pharmacopeia):
-
Amylase 10,000-70,000 USP units/mg Protease 10,000-80,000 USP units/mg Lipase 4,000-40,000 USP units/mg Pancreatin 2,000-6,000 USP units/mg Chymotrypsin 2-5 mg Trypsin 60-100 mg Papain 3,000-30,000 USP units/mg Papaya 30-500 mg -
Protease 40,000 USP units/mg Chymotrypsin 2-7 mg Trypsin 60-100 mg Papaya 30-500 mg -
Amylase 30,000 USP units/mg Protease 40,000 USP units/mg Lipase 30,000 USP units/mg Chymotrypsin 2-7 mg Papaya 30-500 mg -
Amylase 30,000 USP units/mg Protease 40,000-80,000 USP units/mg Lipase 30,000-80,000 USP units/mg Chymotrypsin 2 mg Papain 6,000-30,000 USP units/mg - Other combinations of digestive enzymes may also be used. These enzymes can be in the form of animal or plant derivatives, natural or synthetic.
- In a study conducted by the inventor, sixteen subjects diagnosed with Parkinson's disease and ranging in age from 41 to 71 were examined were examined. Physical symptoms of the disease, such as constipation, lack of bowel movements, tremors, falling, and an inability to walk were monitored and measured over a period of 180 days. The subjects were given a dosage of digestive enzymes 3-5 per day. The dosages were administered in the form of encapsulated tablets, capsules, and sprinkles. The dosages were taken with meals and snacks. The digestive enzyme dosage included, but was not limited to, one or more of the following: amylases, proteases, pancreatin, papain, papaya, lipases, chymotrypsin, and trypsin.
- Ninety-five percent of adults have bowel movements between three and 21 times per week, and this would be considered normal. The most common pattern is one bowel movement a day. However, some people do not have bowel movements every day or the same number of bowel movements each day. Medically speaking, constipation usually is defined as fewer than three bowel movements per week. Severe constipation is defined as less than one bowel movement per week.
- Referring to
FIG. 1 , a majority of the subjects experienced moderate to severe constipation prior to any treatment with digestive enzymes. The severity of the constipation was measured on a scale of 1 to 7, with 1 equaling no constipation and 7 equaling severe constipation. The subjects were monitored at 30, 90, 120 and 180 day intervals. Over the course of the 180 day treatment, the severity of the constipation decreased from severe to moderate to mild in the majority of the subjects. - Referring to
FIG. 2 , the number of bowel movements per week experienced by most of the subjects was lower than normal prior to any treatment with digestive enzymes. The subjects were monitored at 30, 90, 120 and 180 day intervals. Over the course of the 180 day treatment, the number of bowel movements per week increased to 3 or more in the majority of subjects. - Static tremors, or “resting tremors”, are tremors that occurs despite the limb being fully supported and at rest against gravity. They usually progress at the rate of 4-7 Hz (hertz), and are the typical Parkinsonian tremor. The amplitude of the tremor often decrease with sleep, complete relaxation or voluntary activity. Tremors are often the first symptom that people with Parkinson's disease or their family members notice. Initially, the tremors may appear in just one limb (arm or leg) or only on one side of the body. The tremors also may affect the lips, tongue, neck, or eyelids. As the disease progresses, the tremors may spread to both sides of the body, although in some cases the tremors remain on just one side. Emotional and physical stress tend to make the tremors worse.
- Referring to
FIG. 3 , a majority of the subjects experienced severe tremors prior to any treatment with digestive enzymes. The severity of the tremors was measured on a scale of 1 to 7, with 1 equaling no tremors and 7 equaling severe tremors. The subjects were monitored at 30, 90, 120 and 180 day intervals. Over the course of the 180 day treatment, the severity of the tremors decreased from severe to moderate to mild in a majority of the subjects. - Many Parkinson's patients develop gait and balance problems and this can lead to falls. Ambulation is with a stooped posture using a short, shuffling gait. This is primarily due to the loss of balance control. Unfortunately with Parkinson's disease, the muscles become stiff and patients have difficulty swinging their arms when walking which helps in keeping one's balance. They also have episodes of freezing which literally have them “stuck in place” when initiating a step and they exhibit a slight foot drag which makes tripping easy. Persons with Parkinson's have difficulty in judging spatial relationships. Thus, falls often happen when navigating through doorways or through narrow passages.
- Referring to
FIG. 4 , a majority of the subjects experienced an elevated number of falls prior to any treatment with digestive enzymes. The subjects were monitored at 30, 90, 120 and 180 days. Over the course of the 180 day treatment, the number of falls decreased to less than two per week in a majority of the subjects. - Referring to
FIG. 5 , a majority of the subjects experienced severe difficulty in ambulation prior to any treatment with digestive enzymes. The difficulty in ambulation was measured on a scale of 1 to 7, with 1 equaling no difficulty and 7 equaling severe difficulty. The subjects were monitored at 30, 90, 120 and 180 day intervals. Over the course of the 180 day treatment, the difficulty in ambulation decreased from severe to moderate to some or no difficulty in a majority of the subjects. - Fecal chymotrypsin levels were also measured in the 16 subjects and compared to the fecal chymotrypsin levels of 16 subjects who did not have Parkinson's disease. The non-Parkinson's subjects ranged in age from 44 to 77. Fecal chymotrypsin is a sensitive, specific measure of proteolytic activity. Normal levels of chymotrypsin are considered be greater than 8.4 U/gram. Decreased values (less than 4.2 U/gram) suggest diminished pancreatic output (pancreatic insufficiency), hypoacidity of the stomach or cystic fibrosis. Elevated chymotrypsin values suggest rapid transit time, or less likely, a large output of chymotrypsin from the pancreas.
- A stool sample was collected from each of the subjects. Each stool sample was analyzed using an enzymatic photospectrometry analysis to determine the level of fecal chymotrypsin in the stool. Alternatively, other methods, such as the calorimetric method, use of substrates, use of assays, and/or any other suitable method may be used to measure the fecal chymotrypsin levels. The levels of fecal chymotrypsin in the Parkinson's patients was compared to the levels of fecal chymotrypsin in the non-Parkinson's subjects to determine if the Parkinson's patients would benefit from the administration of digestive enzymes.
- Referring to
FIG. 6 , the fecal chymotrypsin levels of the Parkinson's patients ranged from 0.8 to 6.6 U/gram, with a mean of 2.84 U/gram, while the fecal chymotrypsin levels of the non-Parkinson's patients ranged from 9.2. to 47.4 U/gram, with a mean of 28 U/gram. Thus, it can be seen that the fecal chymotrypsin levels of the Parkinson's patients were markedly decreased when compared to the non-Parkinson's subjects. - In summary, the results of the study described herein demonstrate that administration of digestive enzymes benefits individuals having a dysautonomic disorder, such as Parkinson's disease, by ameliorating the symptoms of the disorder. Furthermore, the results of the study indicate that measurement of the fecal chymotrypsin level in individuals having a dysautonomic disorder can determine if the individual will benefit from the administration of digestive enzymes.
- The foregoing description of the embodiments of the invention has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many modifications and variations are possible in light of this disclosure. It is intended that the scope of the invention be limited not by this detailed description, but rather by the claims appended hereto.
Claims (21)
1. A pharmaceutical preparation to treat a dysautonomic disorder in an individual comprising a therapeutically effective amount of digestive enzymes.
2. The pharmaceutical preparation of claim 1 , wherein the dysautonomic disorder is Parkinson's disease.
3. The pharmaceutical preparation of claim 1 , wherein the digestive enzyme is selected from the group consisting of: amylase, lipase, protease, and a combination thereof.
4. The pharmaceutical preparation of claim 1 , wherein the digestive enzyme is further selected from the group consisting of: chymotrypsin, trypsin, pancreatin, papaya, papain, and a combination thereof.
5. The pharmaceutical preparation of claim 1 , wherein the enzymes are derived from a source selected from the group consisting of animal enzymes, plant enzymes, synthetic enzymes, and a combination thereof.
6. The pharmaceutical preparation of claim 1 wherein the preparation is manufactured using a technology selected from the group consisting of Prosolv technology, enteric coating, lipid encapsulation, direct compression, dry granulation, wet granulation, and a combination thereof.
7. The pharmaceutical preparation of claim 1 , wherein the preparation is administered orally via a dosage formulation selected from the group consisting of: pills, tablets, capsules, microcapsules, mini-capsules, time released capsules, mini-tabs, sprinkles, and a combination thereof.
8. The pharmaceutical preparation of claim 3 , wherein the amount of amylase ranges from 10,000 to 70,000 USP units/mg.
9. The pharmaceutical preparation of claim 3 , wherein the amount of protease ranges from 10,000 to 80,000 USP units/mg.
10. The pharmaceutical preparation of claim 3 , wherein the amount of lipase ranges from 4,000 to 80,000 USP units/mg.
11. The pharmaceutical preparation of claim 4 , wherein the amount of pancreatin ranges from 2,000 to 6,000 USP units/mg.
12. The pharmaceutical preparation of claim 4 , wherein the amount of chymotrypsin ranges from 2 to 7 mg.
13. The pharmaceutical preparation of claim 4 , wherein the amount of papain ranges from 3,000 to 30,000 USP units/mg.
14. The pharmaceutical preparation of claim 4 , wherein the amount of papaya ranges from 30 to 500 mg
15. The pharmaceutical preparation of claim 4 , wherein the amount of trypsin ranges from 60 to 100 mg.
16. The pharmaceutical preparation of claim 1 , wherein a symptom of the dysautonomic disorder is ameliorated.
17. The pharmaceutical preparation of claim 1 wherein the symptom of the dysautonomic disorder is selected from the group consisting of: constipation, tremors, falls, difficulty in ambulation, and a combination thereof.
18. A method of treating an individual having a dyautonomic disorder with a therapeutically effective amount of digestive enzymes comprising the steps of:
measuring a level of fecal chymotrypsin in a stool sample of the individual;
comparing the level of fecal chymotrypsin with a normal fecal chymotrypsin level; and administering the digestive enzymes to the individual if the level of fecal chymotrypsin in the individual is less than the normal fecal chymotrypsin level.
19. The method of claim 18 , further comprising the steps of:
administering the digestive enzymes to the individual in order to promote protein digestion; and
administering the digestive enzymes to the individual in order to ameliorate a symptom of the dysautonomic disorder.
20. The method of claim 18 , wherein the stool sample is measured using a technique selected from the group consisting of: enzymatic photospectrometry, colorimetry, treatment with substrates, assays, and a combination thereof.
21. The method of claim 18 , wherein the normal fecal chymotrypsin level is approximately 8.4 U/gram.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22499100P true | 2000-08-14 | 2000-08-14 | |
US09/929,592 US6660831B2 (en) | 2000-08-14 | 2001-08-14 | Method for diagnosing and treating dysautonomia and other dysautonomic conditions |
US10/730,567 US7138123B2 (en) | 2000-08-14 | 2003-12-08 | Methods for diagnosing and treating dysautonomia and other dysautonomic conditions |
US11/555,697 US20070053895A1 (en) | 2000-08-14 | 2006-11-02 | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/555,697 US20070053895A1 (en) | 2000-08-14 | 2006-11-02 | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
US12/046,252 US8778335B2 (en) | 2000-08-14 | 2008-03-11 | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US12/487,868 US8012710B2 (en) | 2000-08-14 | 2009-06-19 | Methods of treating and diagnosing Parkinsons disease and related dysautonomic disorders |
US14/296,091 US20140348881A1 (en) | 2000-08-14 | 2014-06-04 | Method for diagnosing and treating dysautonomia and other dysautonomic conditions |
US14/493,734 US9233146B2 (en) | 2000-08-14 | 2014-09-23 | Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date | |
---|---|---|---|---|
US10/730,567 Continuation-In-Part US7138123B2 (en) | 2000-08-14 | 2003-12-08 | Methods for diagnosing and treating dysautonomia and other dysautonomic conditions |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/046,252 Division US8778335B2 (en) | 2000-08-14 | 2008-03-11 | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US14/493,734 Continuation US9233146B2 (en) | 2000-08-14 | 2014-09-23 | Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070053895A1 true US20070053895A1 (en) | 2007-03-08 |
Family
ID=37830248
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/555,697 Abandoned US20070053895A1 (en) | 2000-08-14 | 2006-11-02 | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
US12/046,252 Active US8778335B2 (en) | 2000-08-14 | 2008-03-11 | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US12/487,868 Active US8012710B2 (en) | 2000-08-14 | 2009-06-19 | Methods of treating and diagnosing Parkinsons disease and related dysautonomic disorders |
US14/296,091 Pending US20140348881A1 (en) | 2000-08-14 | 2014-06-04 | Method for diagnosing and treating dysautonomia and other dysautonomic conditions |
US14/493,734 Active US9233146B2 (en) | 2000-08-14 | 2014-09-23 | Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/046,252 Active US8778335B2 (en) | 2000-08-14 | 2008-03-11 | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US12/487,868 Active US8012710B2 (en) | 2000-08-14 | 2009-06-19 | Methods of treating and diagnosing Parkinsons disease and related dysautonomic disorders |
US14/296,091 Pending US20140348881A1 (en) | 2000-08-14 | 2014-06-04 | Method for diagnosing and treating dysautonomia and other dysautonomic conditions |
US14/493,734 Active US9233146B2 (en) | 2000-08-14 | 2014-09-23 | Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
Country Status (1)
Country | Link |
---|---|
US (5) | US20070053895A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020081628A1 (en) * | 2000-11-16 | 2002-06-27 | Fallon Joan M. | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
US20080161265A1 (en) * | 2005-08-30 | 2008-07-03 | Fallon Joan M | Use of lactulose in the treatment of autism |
US20080166334A1 (en) * | 2004-09-28 | 2008-07-10 | Fallon Joan M | Combination enzyme for cystic fibrosis |
US20080219966A1 (en) * | 1999-12-17 | 2008-09-11 | Fallon Joan M | Methods of treating pervasive development disorders |
US20090232789A1 (en) * | 2008-03-13 | 2009-09-17 | Fallon Joan M | Novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia, and their related symptoms and related disorders of pregnancy |
US20090263372A1 (en) * | 2008-04-18 | 2009-10-22 | Fallon Joan M | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US20090285790A1 (en) * | 2000-08-14 | 2009-11-19 | Fallon Joan M | Methods of treating and diagnosing parkinsons disease and related dysautonomic disorders |
US20090324572A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of williams syndrome |
WO2010002972A1 (en) * | 2008-07-01 | 2010-01-07 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US20100169409A1 (en) * | 2008-08-04 | 2010-07-01 | Fallon Joan M | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain |
US20100260857A1 (en) * | 2009-04-13 | 2010-10-14 | Joan Fallon | Enzyme delivery systems and methods of preparation and use |
WO2012145651A3 (en) * | 2011-04-21 | 2013-01-17 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
US9061033B2 (en) | 2008-10-03 | 2015-06-23 | Curemark Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
Citations (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3322626A (en) * | 1963-06-13 | 1967-05-30 | Pannett Products Inc | Medicinal composition for treating acne and method of using same |
US3574819A (en) * | 1966-12-08 | 1971-04-13 | Ciba Geigy Corp | Pharmaceutical compositions for treating digestive disorders containing 4,7- phenanthrolin - 5,6 - quinone together with pancreatin,bromelin,dehydrocholic acid and 7 - iodo - 5 - chloro-8-hydroxyquinoline |
US3860708A (en) * | 1973-11-15 | 1975-01-14 | Philips Corp | Method of delivering the intestines of human beings from bariumsulphate after barium meal examination |
US3940478A (en) * | 1974-04-29 | 1976-02-24 | Sutures, Inc. | Proteolytic enzymes as adjuncts to antibiotic prophylaxis of contaminated wounds |
US4145410A (en) * | 1976-10-12 | 1979-03-20 | Sears Barry D | Method of preparing a controlled-release pharmaceutical preparation, and resulting composition |
US4280971A (en) * | 1979-06-08 | 1981-07-28 | Kali-Chemie Pharma Gmbh | Process for the production of pancreatin pellets |
US4447412A (en) * | 1983-02-01 | 1984-05-08 | Bilton Gerald L | Enzyme-containing digestive aid compostions |
US4456544A (en) * | 1983-08-05 | 1984-06-26 | Vsesojuzny Nauchno-Issledovatelsky Biotecknichesky Institut | Enzyme-containing detergent composition for presterilization treatment of medical instruments and equipment |
US5324514A (en) * | 1992-06-22 | 1994-06-28 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
US5674532A (en) * | 1989-11-24 | 1997-10-07 | Biochemie Gesellschaft M.B.H. | Pancreatin preparations |
US5858758A (en) * | 1997-05-07 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Human serine protease precursor |
US6011001A (en) * | 1990-08-03 | 2000-01-04 | Vertex Pharmaceuticals, Inc. | Method of protein therapy by orally administering crosslinked protein crystals |
US6187309B1 (en) * | 1999-09-14 | 2001-02-13 | Milkaus Laboratory, Inc. | Method for treatment of symptoms of central nervous system disorders |
US6280726B1 (en) * | 1995-07-21 | 2001-08-28 | New York University | Type II phospholipase A2 and its use in killing Gram-positive bacteria |
US6287585B1 (en) * | 1996-03-06 | 2001-09-11 | Novozymes A/S | Methods for laundry using polycations and enzymes |
US20010023360A1 (en) * | 1999-12-24 | 2001-09-20 | Nelson Chester G. | Dynamic bandwidth monitor and adjuster for remote communications with a medical device |
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US20020001575A1 (en) * | 2000-05-26 | 2002-01-03 | Foreman David J. | Nutritional system for nervous system disorders |
US20020037284A1 (en) * | 2000-08-14 | 2002-03-28 | Fallon Joan M. | Method for diagnosing and treating dysautonomia and other dysautonomic conditions |
US20020061302A1 (en) * | 1999-03-17 | 2002-05-23 | Suntje Sander-Struckmeier | Method for the treatment of diabetes |
US20020081628A1 (en) * | 2000-11-16 | 2002-06-27 | Fallon Joan M. | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US20020090653A1 (en) * | 1999-12-17 | 2002-07-11 | Fallon Joan M. | Methods of treating pervasive development disorders |
US20020103675A1 (en) * | 1999-11-29 | 2002-08-01 | John Vanelli | Apparatus and method for providing consolidated medical information |
US20020119914A1 (en) * | 2000-12-26 | 2002-08-29 | Deguang Zhu | New uses of insulin and pancreatin |
US6534259B1 (en) * | 1997-06-05 | 2003-03-18 | Andrew Wakefield | Regressive behavioral disorder diagnosis |
US6558708B1 (en) * | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
US6562629B1 (en) * | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
US20040005304A1 (en) * | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
US20040029752A1 (en) * | 2000-04-07 | 2004-02-12 | Alex Sava | Process and composition for cleaning medical instruments |
US20040028689A1 (en) * | 2000-07-25 | 2004-02-12 | Borody Thomas Julius | Probiotic recolonisation therapy |
US20040071683A1 (en) * | 1999-12-17 | 2004-04-15 | Fallon Joan M. | Methods for treating pervasive development disorders |
US20040076590A1 (en) * | 2002-07-08 | 2004-04-22 | Wilkins Joe S. | Antibacterial toothpaste and mouthwash formulations |
US6727073B1 (en) * | 1999-11-19 | 2004-04-27 | Binax, Inc. | Method for detecting enteric disease |
US20040101562A1 (en) * | 2000-11-15 | 2004-05-27 | Mario Maio | Microspheres of pancreatic enzymes with high stability and production method thereof |
US6743447B2 (en) * | 2000-03-29 | 2004-06-01 | Roquette Freres | Pulverulent mannitol and process for preparing it |
US20040121002A1 (en) * | 2002-12-23 | 2004-06-24 | Lee Phillip K. | Controlled release encapsulated bioactive substances |
US6783757B2 (en) * | 2000-06-01 | 2004-08-31 | Kirkman Group, Inc. | Composition and method for increasing exorphin catabolism to treat autism |
US6808708B2 (en) * | 1999-10-01 | 2004-10-26 | Prothera, Inc. | Compositions and methods relating to reduction of symptoms of autism |
US6852487B1 (en) * | 1996-02-09 | 2005-02-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US20050079594A1 (en) * | 2002-10-31 | 2005-04-14 | Karine Marion | Method of removing a biofilm |
US20050170479A1 (en) * | 2002-05-03 | 2005-08-04 | Weaver Craig A. | Method for producing lipids by liberation from biomass |
US20050187130A1 (en) * | 2004-02-23 | 2005-08-25 | Brooker Alan T. | Granular laundry detergent composition comprising an anionic detersive surfactant, and low levels of, or no, zeolite builders and phosphate builders |
US20050232894A1 (en) * | 2004-04-20 | 2005-10-20 | Weiner Gregory M | Antimicrobial skin treatment composition and methods for producing and using an antimicrobial skin treatment composition |
US20060105379A1 (en) * | 2001-04-26 | 2006-05-18 | Shujian Wu | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US20060115467A1 (en) * | 2004-12-01 | 2006-06-01 | Pangborn Jon B | Compositions and methods for the treatment of autism |
US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
US7129053B1 (en) * | 1999-10-12 | 2006-10-31 | Dakocytomation Denmark A/S | Immuno-chromatographic rapid assay in order to detect acid-resistant microorganisms in the stool |
US20060259995A1 (en) * | 2002-10-10 | 2006-11-16 | Diversa Corporation | Proteases, nucleic acids encoding them and methods for making and using them |
US20070031399A1 (en) * | 2003-09-23 | 2007-02-08 | Luppo Edens | Use of proline specific endoproteases to hydrolyse peptides and proteins |
US20070092501A1 (en) * | 2005-04-26 | 2007-04-26 | Prothera, Inc. | Compositions and methods relating to reduction of symptoms of autism |
US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
US20070203426A1 (en) * | 2005-10-20 | 2007-08-30 | Kover Arthur J | Method and apparatus for obtaining real time emotional response data over a communications network |
US20080058282A1 (en) * | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US20080057086A1 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
US20080112900A1 (en) * | 2003-07-11 | 2008-05-15 | Laurence Du-Thumm | Chewable Antiplaque Confectionery Dental Composition |
US20080152637A1 (en) * | 2000-08-14 | 2008-06-26 | Fallon Joan M | Methods of treating and diagnosing parkinsons disease and related dysautonomic disorders |
US20080254009A1 (en) * | 2000-06-05 | 2008-10-16 | Finegold Sydney M | Method of treating gastrointestinal diseases associated with species of genus clostridium |
US20080274174A1 (en) * | 2007-02-20 | 2008-11-06 | Giovanni Ortenzi | Stable pancreatic enzyme compositions |
US20090117180A1 (en) * | 2007-02-20 | 2009-05-07 | Giovanni Ortenzi | Stable digestive enzyme compositions |
US20090232789A1 (en) * | 2008-03-13 | 2009-09-17 | Fallon Joan M | Novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia, and their related symptoms and related disorders of pregnancy |
US20090263372A1 (en) * | 2008-04-18 | 2009-10-22 | Fallon Joan M | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US20100092447A1 (en) * | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
US7718169B2 (en) * | 2004-10-14 | 2010-05-18 | Cystic Fibrosis Foundations Therapeutics, Inc. | Compositions and methods for treating pancreatic insufficiency |
US20100169409A1 (en) * | 2008-08-04 | 2010-07-01 | Fallon Joan M | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain |
US20100260857A1 (en) * | 2009-04-13 | 2010-10-14 | Joan Fallon | Enzyme delivery systems and methods of preparation and use |
US20110029922A1 (en) * | 1991-12-23 | 2011-02-03 | Linda Irene Hoffberg | Adaptive pattern recognition based controller apparatus and method and human-factored interface therefore |
US20110081320A1 (en) * | 2009-10-06 | 2011-04-07 | Nubiome, Inc. | Treatment/Cure of Autoimmune Disease |
US20110112005A1 (en) * | 2009-11-12 | 2011-05-12 | Alan Thomas Brooker | Laundry Detergent Composition |
US20110200574A1 (en) * | 2010-02-02 | 2011-08-18 | Jolly James F | Use of proteases for gluten intolerance |
US20120128764A1 (en) * | 2009-02-23 | 2012-05-24 | Aptalis Pharmatech, Inc. | Controlled-release compositions comprising a proton pump inhibitor |
US20120201875A1 (en) * | 2010-10-01 | 2012-08-09 | Aptalis Pharma Limited | Stable low digestive enzyme content formulation |
US20120258149A1 (en) * | 2009-10-21 | 2012-10-11 | Curemark Llc | Methods and Compositions for the Prevention and Treatment of Influenza |
US8437689B2 (en) * | 2003-06-23 | 2013-05-07 | Cardiac Pacemakers, Inc. | Systems, devices, and methods for selectively preventing data transfer from a medical device |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US534514A (en) * | 1895-02-19 | Safety-valve | ||
BE491927A (en) | 1948-10-30 | |||
US3002883A (en) | 1959-07-29 | 1961-10-03 | Dow Chemical Co | Disinfectant compositions |
GB928654A (en) | 1960-10-25 | 1963-06-12 | Philips Nv | Improvements in or relating to the production of pancreatin |
US3357894A (en) | 1963-10-18 | 1967-12-12 | Ct Nat De La Recherche | Proteolytic enzymes of pig pancreas |
DE1517787A1 (en) | 1965-12-06 | 1970-01-29 | Takeda Chemical Industries Ltd | Enzympraeparat and process for its preparation |
GB1509866A (en) * | 1975-06-10 | 1978-05-04 | Johnson & Johnson | Enteric coated digestive enzyme compositions |
US4241046A (en) * | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US5250418A (en) | 1981-10-06 | 1993-10-05 | Boehringer Mannheim Gmbh | Process and reagent for determining the activity of chymotrypsin and trypsin in feces |
EP0115023B1 (en) | 1982-12-30 | 1988-07-27 | Nordmark Arzneimittel GmbH | Process for obtaining pancreatin |
EP0133438A1 (en) | 1983-01-21 | 1985-02-27 | Advanced Drug Technology Corporation | Enzyme ointment |
DE3650184D1 (en) | 1985-12-03 | 1995-02-09 | T Cell Sciences Inc | Free cells t cells antigen receptor and clinical use. |
JPH0475888B2 (en) | 1986-03-31 | 1992-12-02 | Snow Brand Milk Prod Co Ltd | |
US4826679A (en) | 1986-05-23 | 1989-05-02 | Universite De Montreal | Composition and methods for alleviating cystic fibrosis |
CN1039706A (en) | 1988-08-04 | 1990-02-21 | 黄族和 | Method of making artificial fa vegetable |
GB8821049D0 (en) | 1988-09-08 | 1988-10-05 | Health Lab Service Board | Method & composition for treatment & prevention of viral infections |
GB8923788D0 (en) | 1989-10-23 | 1989-12-13 | Unilever Plc | Enzymatic detergent compositions and their use |
CA2037178A1 (en) * | 1990-02-28 | 1991-08-29 | Albert Walter Brzeczko | Deprenyl/l-dopa/carbidopa pharmaceutical composition |
US5190775A (en) | 1991-05-29 | 1993-03-02 | Balchem Corporation | Encapsulated bioactive substances |
US5607863A (en) | 1991-05-29 | 1997-03-04 | Smithkline Diagnostics, Inc. | Barrier-controlled assay device |
JPH04364119A (en) | 1991-06-11 | 1992-12-16 | Tsumura & Co | Bathing agent composition |
IL99628A (en) | 1991-10-02 | 2004-07-25 | Yissum Res Dev Co | Processes for the preparation of cyclic peptides, and pharmaceutical compositions containing them |
WO1993010755A1 (en) | 1991-11-25 | 1993-06-10 | Richardson-Vicks, Inc. | Compositions for regulating skin wrinkles and/or skin atrophy |
GB9207280D0 (en) | 1992-04-02 | 1992-05-13 | Unilever Plc | Skin care method and composition |
WO1993025219A1 (en) | 1992-06-12 | 1993-12-23 | Cephalon, Inc. | Prevention and treatment of peripheral neuropathy |
US5460812A (en) | 1992-06-22 | 1995-10-24 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
DE4227385A1 (en) | 1992-08-19 | 1994-02-24 | Kali Chemie Pharma Gmbh | pancreatin |
GB9218363D0 (en) | 1992-08-28 | 1992-10-14 | Black & Decker Inc | Pivoting power tool with table |
DE4305460C2 (en) | 1993-02-23 | 1997-09-04 | Albert Dr Scheller | Pharmaceutical or cosmetic containing enzymes preparation, processes for their preparation and their use |
TW310277B (en) | 1993-05-21 | 1997-07-11 | Pou Lin Fu Gin Pharm Co | The method of preparing enteric-coated pancreatin granules and its dosage forms |
DE4332985A1 (en) | 1993-09-28 | 1995-03-30 | Konrad Peter Maria Dr Sommer | Pharmaceutical composition for the treatment of exocrine pancreas dysfunction |
GB9403250D0 (en) | 1994-02-21 | 1994-04-13 | Univ Mcgill | Therapeutic use of myelin-associated glycoprotein (mag) |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US20080311554A1 (en) | 1994-05-06 | 2008-12-18 | Slotman Gus J | Methods for monitoring patients with severe sepsis and septic shock and for selecting treatments for these patients |
US5476661A (en) | 1994-10-21 | 1995-12-19 | Elizabeth Arden Co., Division Of Conopco, Inc. | Compositions for topical application to skin, hair and nails |
US5527678A (en) | 1994-10-21 | 1996-06-18 | Vanderbilt University | CagB and CagC genes of helicobacter pylori and related compositions |
AUPN033894A0 (en) | 1994-12-29 | 1995-01-27 | Rowe, J.B. | Prevention of adverse behaviour in humans and animals |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
CA2220451A1 (en) | 1995-05-17 | 1996-11-21 | Cedars-Sinai Medical Center | Methods and compositions for improving digestion and absorption in the small intestine |
US5686311A (en) | 1995-06-23 | 1997-11-11 | The Children's Mercy Hospital | Diagnosis of autism and treatment therefor |
US5952178A (en) | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
US5958875A (en) | 1996-03-29 | 1999-09-28 | The Regents Of The University Of California | Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity |
US5750104A (en) | 1996-05-29 | 1998-05-12 | Digestive Care Inc. | High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith |
GB2318511A (en) | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
US5860932A (en) | 1996-10-24 | 1999-01-19 | Colin Corporation | Blood pressure monitor |
CA2190418A1 (en) | 1996-11-15 | 1998-05-15 | Zhi-Cheng Xiao | Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof |
CA2198317C (en) | 1997-02-24 | 2003-01-07 | Mouhsine El Abboudi | Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof |
NZ337954A (en) | 1997-03-13 | 2001-09-28 | First Opinion Corp | Computerized disease management method adjusts a disease therapy for a patient based on obtained health data |
US6197746B1 (en) | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
US6020310A (en) | 1997-05-19 | 2000-02-01 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
US6482839B1 (en) | 1997-06-02 | 2002-11-19 | Cellegy Pharmaceuticals, Inc. | Pyridine-thiols for treatment of a follicular dermatosis |
GB2347742B (en) | 1997-06-05 | 2001-11-07 | Royal Free Hosp School Med | Pharmaceutical composition for RBD |
KR19990072826A (en) | 1998-02-26 | 1999-09-27 | 우재영 | A process for producing enteric-coated pancreatin granules |
AT429813T (en) * | 1998-10-09 | 2009-05-15 | Gen Mills Inc | Encapsulation of sensitive liquid components into a matrix for recovery of discrete shelf-stable particles |
US6020314A (en) | 1998-08-11 | 2000-02-01 | Milkhaus Laboratory, Inc. | Methods for treatment of neurological disorders |
US6149585A (en) | 1998-10-28 | 2000-11-21 | Sage Health Management Solutions, Inc. | Diagnostic enhancement method and apparatus |
US6168569B1 (en) | 1998-12-22 | 2001-01-02 | Mcewen James Allen | Apparatus and method for relating pain and activity of a patient |
US6753306B2 (en) | 1998-12-23 | 2004-06-22 | Joseph J. Simpson | Germicidal and disinfectant composition |
US7945451B2 (en) | 1999-04-16 | 2011-05-17 | Cardiocom, Llc | Remote monitoring system for ambulatory patients |
US6210950B1 (en) | 1999-05-25 | 2001-04-03 | University Of Medicine And Dentistry Of New Jersey | Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors |
US6153236A (en) | 1999-06-03 | 2000-11-28 | Balchem Corporation | Low melt encapsulation with high laurate canola oil |
US7395216B2 (en) | 1999-06-23 | 2008-07-01 | Visicu, Inc. | Using predictive models to continuously update a treatment plan for a patient in a health care location |
KR100335120B1 (en) * | 1999-08-25 | 2002-05-04 | 박종섭 | Method for forming metalline of semiconductor device |
US20010024660A1 (en) | 1999-09-29 | 2001-09-27 | Ismat Ullah | Enteric coated pharmaceutical composition and method of manufacturing |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6251478B1 (en) | 1999-12-22 | 2001-06-26 | Balchem Corporation | Sensitive substance encapsulation |
US6980958B1 (en) | 2000-01-11 | 2005-12-27 | Zycare, Inc. | Apparatus and methods for monitoring and modifying anticoagulation therapy of remotely located patients |
US6468210B2 (en) | 2000-02-14 | 2002-10-22 | First Opinion Corporation | Automated diagnostic system and method including synergies |
US6261613B1 (en) | 2000-02-15 | 2001-07-17 | General Mills, Inc. | Refrigerated and shelf-stable bakery dough products |
US6399101B1 (en) | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
GB2370839A (en) | 2001-01-06 | 2002-07-10 | Benedikt Timmerman | Immunogenic complex useful for disease control |
CN1150032C (en) | 2001-01-15 | 2004-05-19 | 孙芳梅 | Concentrated granular medicine for treating baby diarrhea and its preparing process |
AR032392A1 (en) | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | Enzyme mixture, a pharmaceutical preparation and utilization of that preparation. |
US7588757B2 (en) | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
US7107996B2 (en) | 2001-04-10 | 2006-09-19 | Ganz Robert A | Apparatus and method for treating atherosclerotic vascular disease through light sterilization |
US7101573B2 (en) | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
US7630911B2 (en) | 2001-10-24 | 2009-12-08 | Qtc Management, Inc. | Method of automated processing of medical data for insurance and disability determinations |
AU2002364750A1 (en) | 2001-12-14 | 2003-06-30 | Solvay Pharmaceuticals Gmbh | Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans |
US6797291B2 (en) | 2002-01-09 | 2004-09-28 | Balchem Corporation | Stable hygroscopic compositions and methods for stabilizing hygroscopic ingredients |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
US7780595B2 (en) | 2003-05-15 | 2010-08-24 | Clinical Decision Support, Llc | Panel diagnostic method and system |
MXPA06001173A (en) | 2003-07-29 | 2006-04-11 | Solvay Pharm Gmbh | Analytical method for pancreatin and comparable compositions. |
US7381698B2 (en) | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
AT473010T (en) | 2004-05-24 | 2010-07-15 | Novozymes As | Enzymes for pharmaceutical use |
ITTO20040390A1 (en) | 2004-06-10 | 2004-09-10 | Roeder 1956 Farmaceutici S P A | Composition, in particular for pharmaceutical use, an antioxidant action, anti-inflammatory and immunostimulant. |
US20050281795A1 (en) | 2004-06-17 | 2005-12-22 | Amano Enzyme Usa., Ltd. And Amano Enzyme,Inc. | Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers |
US7627767B2 (en) * | 2004-06-30 | 2009-12-01 | At&T Intellectual Property I, L.P. | Methods and systems for remotely securing data in a wireless device in a communications network |
WO2006019764A2 (en) | 2004-07-15 | 2006-02-23 | Northstar Neuroscience, Inc. | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
EP1791966B1 (en) | 2004-09-10 | 2014-06-04 | Novozymes North America, Inc. | Methods for preventing, removing, reducing, or disrupting biofilm |
US20100196344A1 (en) | 2005-10-14 | 2010-08-05 | Cystic Fibrosis Foundation Therapeutics, Inc. | Compositions and methods for treating pancreatic insufficiency |
EP1901771A2 (en) | 2005-06-24 | 2008-03-26 | N-Zymeceuticals, Inc. | Nattokinase for reducing whole blood viscosity |
EP2278002B1 (en) | 2005-07-29 | 2017-07-12 | Abbott Laboratories GmbH | Pancreatin with reduced viral content |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
US20070148152A1 (en) | 2005-08-15 | 2007-06-28 | George Shlieout | Process for the manufacture and use of pancreatin micropellet cores |
AU2006281415B2 (en) | 2005-08-15 | 2012-01-19 | Abbott Laboratories Gmbh | Pancreatin micropellet cores suitable for enteric coating |
WO2007053619A2 (en) | 2005-11-01 | 2007-05-10 | Bio-Cat, Inc. | A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency |
US8728521B2 (en) | 2005-12-27 | 2014-05-20 | Hemant N. Joshi | Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells |
CA2637701A1 (en) | 2006-02-02 | 2007-08-09 | Dsm Ip Assets B.V. | Food product comprising a proline specific protease, the preparation thereof and its use for degrading toxic or allergenic gluten peptides |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
EP2032612A1 (en) | 2006-06-23 | 2009-03-11 | Basell Poliolefine Italia S.r.l. | Magnesium chloroalkolate-based catalyst precursors |
US8287858B2 (en) | 2006-08-10 | 2012-10-16 | Jon Barron | Proteolytic enzyme formulations |
US8066986B2 (en) | 2007-02-01 | 2011-11-29 | Master Supplements, Inc. | Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms |
US20080199448A1 (en) | 2007-02-16 | 2008-08-21 | Ross Mairi R | Enzyme composition for improving food digestion |
WO2008127567A1 (en) | 2007-04-13 | 2008-10-23 | Beth Israel Deaconess Medical Center, Inc. | Novel nutritional food products for improved digestion and intestinal absorption |
WO2009109856A2 (en) | 2008-03-07 | 2009-09-11 | Axcan Pharma Inc. | Method for detecting infectious parvovirus in pharmaceutical preparations |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US20090324730A1 (en) | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
EP2318035A4 (en) | 2008-07-01 | 2012-08-01 | Curemark Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
EP2328609A1 (en) | 2008-08-26 | 2011-06-08 | Cystic Fibrosis Foundation Therapeutics, Inc. | Rapidly disintegrating tablets comprising lipase, amylase, and protease |
AT541591T (en) | 2008-11-03 | 2012-02-15 | Nordmark Arzneimittel Gmbh & Co Kg | A method for reducing the viral and microbial load of pancreatin |
EP2373693A4 (en) | 2009-01-06 | 2012-04-25 | Curelon Llc | Compositions and methods for the treatment or the prevention oral infections by e. coli |
ES2668909T3 (en) | 2009-01-06 | 2018-05-23 | Galenagen, Llc | Compositions comprising protease, amylase and lipase for use in the treatment of Staphylococcus aureus infections |
WO2011000924A1 (en) | 2009-07-03 | 2011-01-06 | Abbott Products Gmbh | Spray-dried amylase, pharmaceutical preparations comprising the same and use |
EP2295039B1 (en) | 2009-08-28 | 2013-12-11 | Nordmark Arzneimittel GmbH & Co.KG | Method of preparing pancreatin pellets, in particular pancreatin micropellets, and pancreatin pellets prepared thereby |
EP2616048A4 (en) | 2010-11-19 | 2014-04-02 | Curemark Llc | Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
GB2503852B (en) | 2011-04-21 | 2018-12-12 | Curemark Llc | Compounds for the treatment of neuropsychiatric disorders |
AU2013206890B2 (en) | 2012-01-03 | 2017-09-28 | Curemark, Llc | Methods of treating behavioral symptoms of neurological and mental disorders |
CA2862363A1 (en) | 2012-02-02 | 2013-08-08 | Joan M. Fallon | Enzyme compositions and use thereof for wound healing |
US20130323223A1 (en) | 2012-05-30 | 2013-12-05 | Curemark, Llc | Methods of treating celiac disease |
-
2006
- 2006-11-02 US US11/555,697 patent/US20070053895A1/en not_active Abandoned
-
2008
- 2008-03-11 US US12/046,252 patent/US8778335B2/en active Active
-
2009
- 2009-06-19 US US12/487,868 patent/US8012710B2/en active Active
-
2014
- 2014-06-04 US US14/296,091 patent/US20140348881A1/en active Pending
- 2014-09-23 US US14/493,734 patent/US9233146B2/en active Active
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3322626A (en) * | 1963-06-13 | 1967-05-30 | Pannett Products Inc | Medicinal composition for treating acne and method of using same |
US3574819A (en) * | 1966-12-08 | 1971-04-13 | Ciba Geigy Corp | Pharmaceutical compositions for treating digestive disorders containing 4,7- phenanthrolin - 5,6 - quinone together with pancreatin,bromelin,dehydrocholic acid and 7 - iodo - 5 - chloro-8-hydroxyquinoline |
US3860708A (en) * | 1973-11-15 | 1975-01-14 | Philips Corp | Method of delivering the intestines of human beings from bariumsulphate after barium meal examination |
US3940478A (en) * | 1974-04-29 | 1976-02-24 | Sutures, Inc. | Proteolytic enzymes as adjuncts to antibiotic prophylaxis of contaminated wounds |
US4145410A (en) * | 1976-10-12 | 1979-03-20 | Sears Barry D | Method of preparing a controlled-release pharmaceutical preparation, and resulting composition |
US4280971A (en) * | 1979-06-08 | 1981-07-28 | Kali-Chemie Pharma Gmbh | Process for the production of pancreatin pellets |
US4447412A (en) * | 1983-02-01 | 1984-05-08 | Bilton Gerald L | Enzyme-containing digestive aid compostions |
US4456544A (en) * | 1983-08-05 | 1984-06-26 | Vsesojuzny Nauchno-Issledovatelsky Biotecknichesky Institut | Enzyme-containing detergent composition for presterilization treatment of medical instruments and equipment |
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US5674532A (en) * | 1989-11-24 | 1997-10-07 | Biochemie Gesellschaft M.B.H. | Pancreatin preparations |
US6011001A (en) * | 1990-08-03 | 2000-01-04 | Vertex Pharmaceuticals, Inc. | Method of protein therapy by orally administering crosslinked protein crystals |
US20110029922A1 (en) * | 1991-12-23 | 2011-02-03 | Linda Irene Hoffberg | Adaptive pattern recognition based controller apparatus and method and human-factored interface therefore |
US5324514A (en) * | 1992-06-22 | 1994-06-28 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US7081239B2 (en) * | 1995-05-17 | 2006-07-25 | Cedars-Sinai Medical Center Burns And Allen Research Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
US6558708B1 (en) * | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
US6280726B1 (en) * | 1995-07-21 | 2001-08-28 | New York University | Type II phospholipase A2 and its use in killing Gram-positive bacteria |
US6852487B1 (en) * | 1996-02-09 | 2005-02-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US6287585B1 (en) * | 1996-03-06 | 2001-09-11 | Novozymes A/S | Methods for laundry using polycations and enzymes |
US5858758A (en) * | 1997-05-07 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Human serine protease precursor |
US6534259B1 (en) * | 1997-06-05 | 2003-03-18 | Andrew Wakefield | Regressive behavioral disorder diagnosis |
US20020061302A1 (en) * | 1999-03-17 | 2002-05-23 | Suntje Sander-Struckmeier | Method for the treatment of diabetes |
US7935799B2 (en) * | 1999-08-11 | 2011-05-03 | Cedars-Sinai Medical Center | Methods of treating diarrhea caused by small intestinal bacterial overgrowth |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US20100209507A1 (en) * | 1999-08-11 | 2010-08-19 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions |
US7736622B2 (en) * | 1999-08-11 | 2010-06-15 | Cedars-Sinai Medical Center | Methods of diagnosing small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6562629B1 (en) * | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
US6187309B1 (en) * | 1999-09-14 | 2001-02-13 | Milkaus Laboratory, Inc. | Method for treatment of symptoms of central nervous system disorders |
US6899876B2 (en) * | 1999-10-01 | 2005-05-31 | Prothera, Inc. | Compositions and methods relating to reduction of symptoms of autism |
US6821514B2 (en) * | 1999-10-01 | 2004-11-23 | Prothera, Inc. | Compositions and methods relating to reduction of symptoms of autism |
US6808708B2 (en) * | 1999-10-01 | 2004-10-26 | Prothera, Inc. | Compositions and methods relating to reduction of symptoms of autism |
US7129053B1 (en) * | 1999-10-12 | 2006-10-31 | Dakocytomation Denmark A/S | Immuno-chromatographic rapid assay in order to detect acid-resistant microorganisms in the stool |
US6727073B1 (en) * | 1999-11-19 | 2004-04-27 | Binax, Inc. | Method for detecting enteric disease |
US20020103675A1 (en) * | 1999-11-29 | 2002-08-01 | John Vanelli | Apparatus and method for providing consolidated medical information |
US8012930B2 (en) * | 1999-12-17 | 2011-09-06 | Curemark, Llc | Methods of treating pervasive development disorders |
US20040071683A1 (en) * | 1999-12-17 | 2004-04-15 | Fallon Joan M. | Methods for treating pervasive development disorders |
US20090197289A1 (en) * | 1999-12-17 | 2009-08-06 | Fallon Joan M | Method for confirming a diagnosis of autism |
US20090130081A1 (en) * | 1999-12-17 | 2009-05-21 | Fallon Joan M | Method for treating pervasive development disorders |
US8105584B2 (en) * | 1999-12-17 | 2012-01-31 | Curemark Llc | Method for treating pervasive development disorders |
US20020090653A1 (en) * | 1999-12-17 | 2002-07-11 | Fallon Joan M. | Methods of treating pervasive development disorders |
US20080219966A1 (en) * | 1999-12-17 | 2008-09-11 | Fallon Joan M | Methods of treating pervasive development disorders |
US20060182728A1 (en) * | 1999-12-17 | 2006-08-17 | Joan Fallon | Methods for treating pervasive development disorders |
US8211661B2 (en) * | 1999-12-17 | 2012-07-03 | Curemark, Llc | Method for identifying individuals having a pervasive development disorder amenable to digestive enzyme therapy |
US20060183180A1 (en) * | 1999-12-17 | 2006-08-17 | Fallon Joan M | Methods for treating pervasive development disorders |
US20010023360A1 (en) * | 1999-12-24 | 2001-09-20 | Nelson Chester G. | Dynamic bandwidth monitor and adjuster for remote communications with a medical device |
US6743447B2 (en) * | 2000-03-29 | 2004-06-01 | Roquette Freres | Pulverulent mannitol and process for preparing it |
US20040029752A1 (en) * | 2000-04-07 | 2004-02-12 | Alex Sava | Process and composition for cleaning medical instruments |
US20040209790A1 (en) * | 2000-04-07 | 2004-10-21 | Alex Sava | Process and composition for cleaning medical instruments |
US7608245B2 (en) * | 2000-04-10 | 2009-10-27 | Cedars-Sinai Medical Center | Methods for manipulating satiety |
US7244412B2 (en) * | 2000-04-10 | 2007-07-17 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
US20020001575A1 (en) * | 2000-05-26 | 2002-01-03 | Foreman David J. | Nutritional system for nervous system disorders |
US6783757B2 (en) * | 2000-06-01 | 2004-08-31 | Kirkman Group, Inc. | Composition and method for increasing exorphin catabolism to treat autism |
US20080254009A1 (en) * | 2000-06-05 | 2008-10-16 | Finegold Sydney M | Method of treating gastrointestinal diseases associated with species of genus clostridium |
US20040028689A1 (en) * | 2000-07-25 | 2004-02-12 | Borody Thomas Julius | Probiotic recolonisation therapy |
US20020037284A1 (en) * | 2000-08-14 | 2002-03-28 | Fallon Joan M. | Method for diagnosing and treating dysautonomia and other dysautonomic conditions |
US20080152637A1 (en) * | 2000-08-14 | 2008-06-26 | Fallon Joan M | Methods of treating and diagnosing parkinsons disease and related dysautonomic disorders |
US20040101562A1 (en) * | 2000-11-15 | 2004-05-27 | Mario Maio | Microspheres of pancreatic enzymes with high stability and production method thereof |
US20020081628A1 (en) * | 2000-11-16 | 2002-06-27 | Fallon Joan M. | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US20020119914A1 (en) * | 2000-12-26 | 2002-08-29 | Deguang Zhu | New uses of insulin and pancreatin |
US20060105379A1 (en) * | 2001-04-26 | 2006-05-18 | Shujian Wu | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
US7285633B2 (en) * | 2001-04-26 | 2007-10-23 | Bristol-Myers Squibb Company | Metalloprotease highly expressed in the testis, MMP-29 |
US20050170479A1 (en) * | 2002-05-03 | 2005-08-04 | Weaver Craig A. | Method for producing lipids by liberation from biomass |
US20040005304A1 (en) * | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
US20040076590A1 (en) * | 2002-07-08 | 2004-04-22 | Wilkins Joe S. | Antibacterial toothpaste and mouthwash formulations |
US20060259995A1 (en) * | 2002-10-10 | 2006-11-16 | Diversa Corporation | Proteases, nucleic acids encoding them and methods for making and using them |
US20050079594A1 (en) * | 2002-10-31 | 2005-04-14 | Karine Marion | Method of removing a biofilm |
US20040121002A1 (en) * | 2002-12-23 | 2004-06-24 | Lee Phillip K. | Controlled release encapsulated bioactive substances |
US8437689B2 (en) * | 2003-06-23 | 2013-05-07 | Cardiac Pacemakers, Inc. | Systems, devices, and methods for selectively preventing data transfer from a medical device |
US20080112900A1 (en) * | 2003-07-11 | 2008-05-15 | Laurence Du-Thumm | Chewable Antiplaque Confectionery Dental Composition |
US20070031399A1 (en) * | 2003-09-23 | 2007-02-08 | Luppo Edens | Use of proline specific endoproteases to hydrolyse peptides and proteins |
US20050187130A1 (en) * | 2004-02-23 | 2005-08-25 | Brooker Alan T. | Granular laundry detergent composition comprising an anionic detersive surfactant, and low levels of, or no, zeolite builders and phosphate builders |
US20050232894A1 (en) * | 2004-04-20 | 2005-10-20 | Weiner Gregory M | Antimicrobial skin treatment composition and methods for producing and using an antimicrobial skin treatment composition |
US20080166334A1 (en) * | 2004-09-28 | 2008-07-10 | Fallon Joan M | Combination enzyme for cystic fibrosis |
US20100233218A1 (en) * | 2004-09-28 | 2010-09-16 | Curemark Llc | Combination enzyme for cystic fibrosis |
US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
US7718169B2 (en) * | 2004-10-14 | 2010-05-18 | Cystic Fibrosis Foundations Therapeutics, Inc. | Compositions and methods for treating pancreatic insufficiency |
US20080112944A1 (en) * | 2004-12-01 | 2008-05-15 | Kirkman Group, Inc. | Compositions and methods for the treatment of autism |
US20060115467A1 (en) * | 2004-12-01 | 2006-06-01 | Pangborn Jon B | Compositions and methods for the treatment of autism |
US20070092501A1 (en) * | 2005-04-26 | 2007-04-26 | Prothera, Inc. | Compositions and methods relating to reduction of symptoms of autism |
US20080058282A1 (en) * | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US20080161265A1 (en) * | 2005-08-30 | 2008-07-03 | Fallon Joan M | Use of lactulose in the treatment of autism |
US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
US20070203426A1 (en) * | 2005-10-20 | 2007-08-30 | Kover Arthur J | Method and apparatus for obtaining real time emotional response data over a communications network |
US20080057086A1 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
US20090117180A1 (en) * | 2007-02-20 | 2009-05-07 | Giovanni Ortenzi | Stable digestive enzyme compositions |
US8221747B2 (en) * | 2007-02-20 | 2012-07-17 | Aptalis Pharma Limited | Stable pancreatic enzyme compositions |
US20080274174A1 (en) * | 2007-02-20 | 2008-11-06 | Giovanni Ortenzi | Stable pancreatic enzyme compositions |
US20090232789A1 (en) * | 2008-03-13 | 2009-09-17 | Fallon Joan M | Novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia, and their related symptoms and related disorders of pregnancy |
US20090263372A1 (en) * | 2008-04-18 | 2009-10-22 | Fallon Joan M | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US20120070504A1 (en) * | 2008-04-18 | 2012-03-22 | Curemark Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US20100169409A1 (en) * | 2008-08-04 | 2010-07-01 | Fallon Joan M | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain |
US20100092447A1 (en) * | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
US20120128764A1 (en) * | 2009-02-23 | 2012-05-24 | Aptalis Pharmatech, Inc. | Controlled-release compositions comprising a proton pump inhibitor |
US20100260857A1 (en) * | 2009-04-13 | 2010-10-14 | Joan Fallon | Enzyme delivery systems and methods of preparation and use |
US20110081320A1 (en) * | 2009-10-06 | 2011-04-07 | Nubiome, Inc. | Treatment/Cure of Autoimmune Disease |
US20120258149A1 (en) * | 2009-10-21 | 2012-10-11 | Curemark Llc | Methods and Compositions for the Prevention and Treatment of Influenza |
US20110112005A1 (en) * | 2009-11-12 | 2011-05-12 | Alan Thomas Brooker | Laundry Detergent Composition |
US20110200574A1 (en) * | 2010-02-02 | 2011-08-18 | Jolly James F | Use of proteases for gluten intolerance |
US20120201875A1 (en) * | 2010-10-01 | 2012-08-09 | Aptalis Pharma Limited | Stable low digestive enzyme content formulation |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9624526B2 (en) | 1999-12-17 | 2017-04-18 | Curemark Llc | Method for treating pervasive development disorders |
US9624525B2 (en) | 1999-12-17 | 2017-04-18 | Curemark, Llc | Method for treating pervasive development disorders |
US8613918B2 (en) | 1999-12-17 | 2013-12-24 | Curemark Llc | Method for treating pervasive development disorders |
US8211661B2 (en) | 1999-12-17 | 2012-07-03 | Curemark, Llc | Method for identifying individuals having a pervasive development disorder amenable to digestive enzyme therapy |
US20080219966A1 (en) * | 1999-12-17 | 2008-09-11 | Fallon Joan M | Methods of treating pervasive development disorders |
US20090197289A1 (en) * | 1999-12-17 | 2009-08-06 | Fallon Joan M | Method for confirming a diagnosis of autism |
US8163278B2 (en) | 1999-12-17 | 2012-04-24 | Curemark Llc | Methods for treating pervasive development disorders |
US8105584B2 (en) | 1999-12-17 | 2012-01-31 | Curemark Llc | Method for treating pervasive development disorders |
US8815233B2 (en) | 1999-12-17 | 2014-08-26 | Curemark Llc | Method for treating pervasive development disorders |
US8012930B2 (en) | 1999-12-17 | 2011-09-06 | Curemark, Llc | Methods of treating pervasive development disorders |
US8008036B2 (en) | 1999-12-17 | 2011-08-30 | Curemark, Llc | Method for identifying autistic individuals amenable to digestive enzyme therapy |
US20090285790A1 (en) * | 2000-08-14 | 2009-11-19 | Fallon Joan M | Methods of treating and diagnosing parkinsons disease and related dysautonomic disorders |
US8012710B2 (en) | 2000-08-14 | 2011-09-06 | Curemark, Llc | Methods of treating and diagnosing Parkinsons disease and related dysautonomic disorders |
US9233146B2 (en) | 2000-08-14 | 2016-01-12 | Curemark, Llc | Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US8778335B2 (en) | 2000-08-14 | 2014-07-15 | Curemark, Llc | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US9377459B2 (en) | 2000-11-16 | 2016-06-28 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8921054B2 (en) | 2000-11-16 | 2014-12-30 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8580522B2 (en) | 2000-11-16 | 2013-11-12 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US20020081628A1 (en) * | 2000-11-16 | 2002-06-27 | Fallon Joan M. | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US20080166334A1 (en) * | 2004-09-28 | 2008-07-10 | Fallon Joan M | Combination enzyme for cystic fibrosis |
US20100233218A1 (en) * | 2004-09-28 | 2010-09-16 | Curemark Llc | Combination enzyme for cystic fibrosis |
US20080161265A1 (en) * | 2005-08-30 | 2008-07-03 | Fallon Joan M | Use of lactulose in the treatment of autism |
US8673877B2 (en) | 2005-08-30 | 2014-03-18 | Curemark, Llc | Use of lactulose in the treatment of autism |
US9345721B2 (en) | 2005-08-30 | 2016-05-24 | Curemark, Llc | Use of lactulose in the treatment of autism |
US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
WO2009114757A2 (en) | 2008-03-13 | 2009-09-17 | Fallon Joan M | A novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia and their related symptoms and related disorders of pregnancy |
US9023344B2 (en) | 2008-03-13 | 2015-05-05 | Curemark, Llc | Method of treating toxemia |
EP2257305A4 (en) * | 2008-03-13 | 2013-04-03 | Curemark Llc | A novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia and their related symptoms and related disorders of pregnancy |
EP3050571A1 (en) * | 2008-03-13 | 2016-08-03 | Curemark, Llc | Digestive enzyme preparation for eclampsia |
US9925250B2 (en) | 2008-03-13 | 2018-03-27 | Curemark, Llc | Method of treating proteinuria in pregnancy |
US9408895B2 (en) | 2008-03-13 | 2016-08-09 | Curemark, Llc | Method of treating pregnancy-induced hypertension |
US20090232789A1 (en) * | 2008-03-13 | 2009-09-17 | Fallon Joan M | Novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia, and their related symptoms and related disorders of pregnancy |
EP2257305A2 (en) * | 2008-03-13 | 2010-12-08 | Joan M. Fallon | A novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia and their related symptoms and related disorders of pregnancy |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8486390B2 (en) | 2008-04-18 | 2013-07-16 | Curemark Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US8318158B2 (en) | 2008-04-18 | 2012-11-27 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US9687534B2 (en) | 2008-04-18 | 2017-06-27 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US9017665B2 (en) | 2008-04-18 | 2015-04-28 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US20090263372A1 (en) * | 2008-04-18 | 2009-10-22 | Fallon Joan M | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US20090324572A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of williams syndrome |
WO2010002972A1 (en) * | 2008-07-01 | 2010-01-07 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US20110182818A1 (en) * | 2008-07-01 | 2011-07-28 | Fallon Joan M | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US20100169409A1 (en) * | 2008-08-04 | 2010-07-01 | Fallon Joan M | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain |
US9687535B2 (en) | 2008-10-03 | 2017-06-27 | Curemark, Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9061033B2 (en) | 2008-10-03 | 2015-06-23 | Curemark Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
US9895427B2 (en) | 2009-01-06 | 2018-02-20 | Galenagen, Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
CN105435217A (en) * | 2009-04-13 | 2016-03-30 | 柯尔马克有限责任公司 | Enzyme delivery systems and methods of preparations and use |
EP2418941A4 (en) * | 2009-04-13 | 2014-01-08 | Curemark Llc | Enzyme delivery systems and methods of preparations and use |
EP2418941A1 (en) * | 2009-04-13 | 2012-02-22 | Curemark, Llc | Enzyme delivery systems and methods of preparations and use |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US9931302B2 (en) | 2009-04-13 | 2018-04-03 | Curemark , LLC | Enzyme delivery systems and methods of preparation and use |
US9415014B2 (en) | 2009-04-13 | 2016-08-16 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US10098844B2 (en) | 2009-04-13 | 2018-10-16 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US20100260857A1 (en) * | 2009-04-13 | 2010-10-14 | Joan Fallon | Enzyme delivery systems and methods of preparation and use |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
JP2014512390A (en) * | 2011-04-21 | 2014-05-22 | キュアマーク リミテッド ライアビリティ カンパニー | Compounds for the treatment of neuropsychiatric disorders |
AU2012245287B2 (en) * | 2011-04-21 | 2017-04-13 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
JP2016216494A (en) * | 2011-04-21 | 2016-12-22 | キュアマーク リミテッド ライアビリティ カンパニー | Compounds for the treatment of neuropsychiatric disorders |
US9492515B2 (en) | 2011-04-21 | 2016-11-15 | Curemark, Llc | Method of treatment of schizophreniform disorder |
GB2503852B (en) * | 2011-04-21 | 2018-12-12 | Curemark Llc | Compounds for the treatment of neuropsychiatric disorders |
GB2503852A (en) * | 2011-04-21 | 2014-01-08 | Curemark Llc | Compounds for the treatment of neuropsychiatric disorders |
US20140127184A1 (en) * | 2011-04-21 | 2014-05-08 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
CN103619348A (en) * | 2011-04-21 | 2014-03-05 | 柯尔马克有限责任公司 | Compounds for the treatment of neuropsychiatric disorders |
EP3305317A1 (en) * | 2011-04-21 | 2018-04-11 | Curemark LLC | Compounds for the treatment of neuropsychiatric disorders |
US8980252B2 (en) * | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
WO2012145651A3 (en) * | 2011-04-21 | 2013-01-17 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
Also Published As
Publication number | Publication date |
---|---|
US9233146B2 (en) | 2016-01-12 |
US20090285790A1 (en) | 2009-11-19 |
US8778335B2 (en) | 2014-07-15 |
US20080152637A1 (en) | 2008-06-26 |
US8012710B2 (en) | 2011-09-06 |
US20150023944A1 (en) | 2015-01-22 |
US20140348881A1 (en) | 2014-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hadorn et al. | Pancreozymin secretin test of exocrine pancreatic funtion in cystic fribrosis and the significance of the result for the pathogenesis of the disease. | |
Greydanus et al. | Neurohormonal factors in functional dyspepsia: insights on pathophysiological mechanisms | |
Riccardi | Mast-cell stabilization to decrease neurofibroma growth: preliminary experience with ketotifen | |
US6139845A (en) | Method for treating cancer with a neurotoxin | |
Brien et al. | Bromelain as a treatment for osteoarthritis: a review of clinical studies | |
US6783757B2 (en) | Composition and method for increasing exorphin catabolism to treat autism | |
Camilleri | Management of the irritable bowel syndrome | |
Fujita et al. | Effects of an ACE-inhibitory agent, katsuobushi oligopeptide, in the spontaneously hypertensive rat and in borderline and mildly hypertensive subjects | |
Gorelick et al. | Cerulein-induced pancreatitis | |
Blei et al. | Hepatic encephalopathy | |
Sander et al. | Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide | |
Hamosh et al. | Pharyngeal lipase and digestion of dietary triglyceride in man. | |
Laugier et al. | Changes in pancreatic exocrine secretion with age: pancreatic exocrine secretion does decrease in the elderly | |
Apte et al. | Alcohol-induced pancreatic injury | |
Aihara et al. | Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension | |
Sinaasappel et al. | Nutrition in patients with cystic fibrosis: a European Consensus | |
Bhardwaj et al. | A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis | |
Casellini et al. | Clinical manifestations and current treatment options for diabetic neuropathies | |
MacFabe et al. | Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders | |
Polak et al. | Vipergic nerves in the penis | |
Karne et al. | Etiopathogenesis of acute pancreatitis | |
US6764831B2 (en) | Methods and compositions for pain management | |
Abrams et al. | Lingual lipase in cystic fibrosis. Quantitation of enzyme activity in the upper small intestine of patients with exocrine pancreatic insufficiency. | |
US20110200574A1 (en) | Use of proteases for gluten intolerance | |
US7381698B2 (en) | Methods for treatment of acute pancreatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CUREMARK, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FALLON, JOAN M.;REEL/FRAME:022626/0948 Effective date: 20090408 |